2018
DOI: 10.1182/bloodadvances.2017008110
|View full text |Cite
|
Sign up to set email alerts
|

Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms

Abstract: Key Points• RTEL1 variants associate with AA, idiopathic cytopenias, and hypocellular myelodysplastic syndromes.• Detailed clinical/family history, functional assays, and in silico tools are critical for interpreting the pathogenicity of RTEL1 variants.Biallelic germline mutations in RTEL1 (regulator of telomere elongation helicase 1) result in pathologic telomere erosion and cause dyskeratosis congenita. However, the role of RTEL1 mutations in other bone marrow failure (BMF) syndromes and myeloid neoplasms, a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
38
1
2

Year Published

2018
2018
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 46 publications
(45 citation statements)
references
References 35 publications
4
38
1
2
Order By: Relevance
“…This variant, classed "likely pathogenic" in ClinVar, was identified in 3 unrelated patients with autosomal-recessive dyskeratosis congenita (a disease of telomere attrition), in compound heterozygosity with another RTEL1 variant. 19 Heterozygous RTEL1 variants are associated with bone marrow failure and myeloid neoplasms, 20 although the effects on DS-ALL risk have not been reported. Common genetic variants in the region are associated with interindividual variation in telomere length and confer risk of pediatric cancers, including ALL.…”
Section: Resultsmentioning
confidence: 99%
“…This variant, classed "likely pathogenic" in ClinVar, was identified in 3 unrelated patients with autosomal-recessive dyskeratosis congenita (a disease of telomere attrition), in compound heterozygosity with another RTEL1 variant. 19 Heterozygous RTEL1 variants are associated with bone marrow failure and myeloid neoplasms, 20 although the effects on DS-ALL risk have not been reported. Common genetic variants in the region are associated with interindividual variation in telomere length and confer risk of pediatric cancers, including ALL.…”
Section: Resultsmentioning
confidence: 99%
“…49 Biallelic mutations in regulator of telomere elongation helicase 1 (RTEL1), which encodes a protein critical to telomere homeostasis, is a known cause of congenital bone marrow failure, but has been identified in 1%-2% of AA cases; most RTEL1 variants, however, are felt not to be pathogenic in the latter condition. 50 The degree of telomere length shortening or erosion has been shown to correlate with the severity of AA, risk of relapse, overall survival, and risk of clonal evolution (via acquisition of new cytogenetic aberrancy) to conditions such as myelodysplastic syndrome (MDS), which will be discussed in more detail later. 51 Telomere length shortening in cases of AA is likely insufficient to lead to AA and ultimately calls into question the distinction between acquired and inherited bone marrow failure syndromes such as AA given it frequently occurs in adult patients without a clear family history of such.…”
Section: Telomere Homeos Ta S Is Pathologymentioning
confidence: 99%
“…Biallelic germline mutations have been identified that clinically manifest with the dyskeratosis congenita phenotype and Hoyeraal-Hreidarsson syndrome [106]. Of relevance to this diagnostic workup, Marsh et al [107] have recently reported that heterozygous RTEL1 variants classified as likely pathogenic can be associated with unexplained cytopenias, AA, and hMDS, seen both at an early age and in adulthood. These variants had variable penetrance, and it was noted that telomere length analysis alone may not detect all primary telomere defects, as RTEL1 variants were detected that were associated with eroded 3′ overhangs only.…”
Section: Delineating Immune Signatures In Lr-mdsmentioning
confidence: 99%
“…Analyses of GATA2 mutational status are also highly relevant given the well-documented predisposition to MDS [109][110][111]. Lastly, a range of other germline mutations may present with late-onset MDS and these should always be considered dependent on phenotype and history (Table 6) [103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118][119][120][121].…”
Section: Delineating Immune Signatures In Lr-mdsmentioning
confidence: 99%